Disease Landscape and Forecast Insights

No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current…

Although TNF-α inhibitors revolutionized the treatment landscape for moderate to severe Crohn’s disease (CD), considerable unmet need remains. For instance, a notable percentage of patients do…

Type 2 diabetes (T2D) is a complex metabolic disorder characterized by a declining ability to produce or utilize insulin. The chronic and progressive nature of the disease, as well as its…

The positive symptoms of schizophrenia (e.g., hallucinations, delusions) are a symptom domain of schizophrenia that affects approximately 83% of the 3.2 million diagnosed prevalent cases of…

Decision Resources Group (DRG) estimates that 80% of the more than 3 million diagnosed prevalent cases of schizophrenia within our surveyed markets (i.e., United States, France, Germany, and United…

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the United States and Europe. The majority of patients with advanced AMD have the wet form of the…

An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS…

In the last ten years, TNF-α inhibitors have transformed the treatment of axial spondyloarthritis, including ankylosing spondylitis and nonradiographic axial spondyloarthritis, and have brought…

Despite advances in treatment, rates of mortality and hospitalization for worsening heart failure remain high among CHF patients, and development of therapies with improved efficacy is one of the…

Despite the recent launches of several new therapies, adding to the range of pharmacotherapies available for treating PAH, and contributing to the complexity of the PAH treatment algorithm, a…

Lennox-Gastaut syndrome (LGS) is a severe, pediatric-onset epilepsy syndrome characterized by developmental delay or regression, multiple seizure types, and electroencephalographic abnormalities…

The most common problems associated with treating dyslipidemia are identifying patients who need to be treated, determining how aggressively they should be treated, and then encouraging them to…